Differential Phospho‐Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease
Sign Up to like & getrecommendations! Published in 2022 at "Movement Disorders"
DOI: 10.1002/mds.28927
Abstract: The clinicopathological phenotype of G2019S LRRK2‐associated Parkinson's disease (L2PD) is similar to idiopathic Parkinson's disease (iPD), and G2019S LRRK2 nonmanifesting carriers (L2NMCs) are at increased risk for development of PD. With various therapeutic strategies in… read more here.
Keywords: signatures blood; phospho signatures; differential phospho; parkinson disease ... See more keywords
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice
Sign Up to like & getrecommendations! Published in 2018 at "Neurobiology of Disease"
DOI: 10.1016/j.nbd.2018.08.018
Abstract: Fibrillization of α-synuclein is instrumental for the development of Parkinson's disease (PD), thus modulating this process can have profound impact on disease initiation/progression. Here, the impact of the p.G2019S mutation of leucine-rich repeat kinase 2… read more here.
Keywords: month old; g2019s lrrk2; syn; g2019s ... See more keywords
In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
Sign Up to like & getrecommendations! Published in 2018 at "Stem cells and development"
DOI: 10.1089/scd.2017.0286
Abstract: Leucine-rich repeat kinase 2 (LRRK2) G2019S (glycine to serine) is the most common mutation associated with sporadic and familial Parkinson's disease (PD) with 80% penetrance by age 70. This mutation is found worldwide, with up… read more here.
Keywords: leucine rich; kinase; pathology; g2019s ... See more keywords